| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capsaicin is a chemical compound that gives chili peppers their spicy flavor and heat. Biological activity, capsaicin has been reported to exhibit a range of effects, including: Pain relief: 10-50 μM Anti-inflammatory activity: 20-50 μM Antioxidant activity: 10-100 μM Anti-cancer activity: 50-100 μM Cardiovascular health: 20-50 μM Approximate μM concentrations of capsaicin, the active compound in chili peppers, that can be achieved with different amounts of chili peppers: 1 teaspoon of dried chili pepper flakes (5g):~10-50 μM of capsaicin 1 tablespoon of dried chili pepper flakes (15g): ~30-150 μM of capsaicin 1 cup of fresh chili peppers (100g): ~100-500 μM of capsaicin 1 teaspoon of chili pepper extract (5g): ~100-500 μM of capsaicin 1 tablespoon of chili pepper extract (15g): ~300-1500 μM of capsaicin Approximate μM concentrations of capsaicin in various foods that contain capsaicin: Jalapeño peppers: 1 pepper (20g): ~20-100 μM of capsaicin 2–8 mg/100g of fresh Jalapeño Serrano peppers: 1 pepper (10g): ~10-50 μM of capsaicin 5–15 mg/100g Cayenne peppers: 1 pepper (10g): ~50-200 μM of capsaicin Habanero peppers: 1 pepper (20g): ~100-500 μM of capsaicin 15–30 mg/100g Ghost peppers: 1 pepper (20g): ~200-1000 μM of capsaicin Hot sauce: 1 teaspoon (5g): ~10-50 μM of capsaicin Chili flakes: 1 teaspoon (5g): ~10-50 μM of capsaicin Spicy sauces and marinades: 1 tablespoon (15g): ~10-50 μM of capsaicin Cayenne Pepper Powder – Approximate capsaicin content: roughly 5–20 mg/g (15-30g human for 100uM?) -IC50 in Cancer Cell Lines: Approximately 50–300 µM (consume 150mg of capsaican not possible?) -IC50 in Normal Cell Lines: Generally higher—often 2–3 times greater Pathways: -disrupting mitochondrial membrane potential, leading to cytochrome c release and subsequent activation of caspases -Activation of TRPV1: resulting in increased intracellular calcium levels -capsaicin can lead to increased production of ROS within cancer cells -Inhibition of NF-κB -Inhibit PI3K/AKT/mTOR signaling -STAT3 Inhibition -Cell Cycle Arrest -reduce the expression of vascular endothelial growth factor (VEGF) -COX-2 -capsaicin is a natural ADAM10 activator and shows potential to attenuate amyloid pathology and protect against AD Capsaicin — capsaicin is a pungent vanilloid alkaloid phytochemical from Capsicum peppers and the principal TRPV1 agonist responsible for chili heat. It is best classified as a natural product / small-molecule vanilloid with approved topical analgesic use but no established anticancer indication. Standard abbreviations include CAP and CAPS. In cancer literature it is a pleiotropic stressor whose dominant preclinical effects usually converge on Ca2+ influx, mitochondrial dysfunction, ROS generation, suppression of pro-survival signaling, and apoptosis, but its biology is context- and concentration-dependent, with occasional low-dose pro-migratory / pro-metastatic signaling reported. Primary mechanisms (ranked):
Bioavailability / PK relevance: Capsaicin is lipophilic, rapidly absorbed, and rapidly metabolized, with substantial first-pass limitation after oral exposure. Human oral PK from a capsicum preparation containing 26.6 mg capsaicin produced a Cmax of about 2.47 ng/mL at ~47 minutes, while the FDA-approved 8% topical system produced transient systemic exposure usually below 5 ng/mL, with a highest detected plasma level of 4.6 ng/mL. Delivery is therefore a major translation constraint for anticancer use, and formulation-based approaches are often invoked to overcome short half-life, irritancy, and exposure limits. In-vitro vs systemic exposure relevance: This is a major limitation. Many anticancer cell studies use roughly 10–300 µM, whereas reported human plasma exposures from oral or approved topical use are in the low ng/mL range, approximately ~0.008–0.015 µM, i.e., orders of magnitude lower than many cytotoxic in-vitro concentrations. Accordingly, direct systemic tumoricidal translation from standard dietary or approved topical exposure is weak unless local delivery, sustained-release systems, or substantially altered formulations are used. Clinical evidence status: Anticancer evidence is predominantly preclinical, with in-vitro and some in-vivo support across several tumor types. There is no regulatory approval for cancer treatment. Human oncology use is currently much more credible as supportive care for neuropathic pain, especially chemotherapy-induced peripheral neuropathy, where topical high-concentration capsaicin patches are being studied and used off-label / investigationally, rather than as a direct antitumor therapy. Mechanistic Table
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product) -Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells -HIF1A induces the expression of vascular endothelial growth factor (VEGF) -High HIF-1α expression is associated with Poor prognosis -Low HIF-1α expression is associated with Better prognosis -Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism. -Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis Key mediators of aerobic glycolysis regulated by HIF-1α. -GLUT-1 → regulation of the flux of glucose into cells. -HK2 → catalysis of the first step of glucose metabolism. -PKM2 → regulation of rate-limiting step of glycolysis. -Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis. -LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate; HIF-1α Inhibitors: -Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate). -Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions. -EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity. -Emodin: reduce HIF-1α expression. (under hypoxia). -Apigenin: inhibit HIF-1α accumulation. |
| 5842- | CAP, | Capsaicin: Current Understanding of Its Mechanisms and Therapy of Pain and Other Pre-Clinical and Clinical Uses |
| - | Review, | Nor, | NA | - | Review, | Diabetic, | NA |
| 1259- | CAP, | Capsaicin inhibits HIF-1α accumulation through suppression of mitochondrial respiration in lung cancer cells |
| - | in-vitro, | Lung, | H1299 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | H2009 |
| 2446- | SFN, | CAP, | The Molecular Effects of Sulforaphane and Capsaicin on Metabolism upon Androgen and Tip60 Activation of Androgen Receptor |
| - | in-vitro, | Pca, | LNCaP |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:55 Target#:143 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid